4//SEC Filing
TANG KEVIN 4
Accession 0001415889-25-021066
CIK 0001600620other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:31 PM ET
Size
8.8 KB
Accession
0001415889-25-021066
Insider Transaction Report
Form 4
TANG KEVIN C
Director
Transactions
- Purchase
Common Shares
2025-08-05$11.68/sh+200,000$2,336,000→ 11,329,500 total(indirect: By LP) - Purchase
Common Shares
2025-08-04$11.34/sh+100,000$1,134,000→ 11,129,500 total(indirect: By LP) - Purchase
Common Shares
2025-08-01$10.12/sh+1,000,000$10,120,000→ 11,029,500 total(indirect: By LP)
Footnotes (4)
- [F1]The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $9.23 to $10.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4.
- [F2]Tang Capital Partners, LP ("TCP") beneficially owns 6,371,711 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI.
- [F3]These shares were purchased in multiple transactions ranging from $11.11 to $11.48.
- [F4]These shares were purchased in multiple transactions ranging from $11.49 to $11.80.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001178579
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 5:31 PM ET
- Size
- 8.8 KB